Kamuvudine-9: A Comprehensive Report on a Novel Inflammasome Inhibitor

I. Introduction and Overview of Kamuvudine-9

Kamuvudine-9, a novel therapeutic agent under development, represents a focused effort to address a range of debilitating degenerative and inflammatory diseases. This report synthesizes available information on its chemical identity, the rationale behind its development, its proposed mechanism of action, preclinical findings, ongoing clinical investigations, and its intellectual property and regulatory landscape. The primary developer of Kamuvudine-9 is Inflammasome Therapeutics.[1]

A. Nomenclature and Chemical Identity

Kamuvudine-9 is the primary designation for this investigational compound, often referred to by the shorthand K-9 in scientific literature and company communications.[2] An important synonym identified in patent literature is 3Et-3TC [14], which indicates its nature as a tri-ethyl derivative of lamivudine (3TC), a well-known nucleoside reverse transcriptase inhibitor (NRTI).

Chemically, Kamuvudine-9 is classified as an NRTI derivative; specifically, it is an alkylated derivative of lamivudine.[1] The definitive chemical structure and name for 3Et-3TC (Kamuvudine-9) are provided in patent documents, such as WO2016138425A1 and EP4215527NWB1, as 4-(diethylamino)-1-[2-(ethoxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one.[14]

The molecular weight (MW) of Kamuvudine-9 (K-9), consistent with its identity as an alkylated lamivudine derivative, is reported as approximately 271.34 g/mol.[6] This is distinct from the parent compound lamivudine, which has a molecular weight of 229.26 g/mol.[18]